Advances in Therapeutic Strategies in Gynecological Malignant Tumors—2nd Edition
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 8
Special Issue Editor
Interests: gynecologic malignancies; urogenital carcinomas; breast cancer; predictive biomarkers; DNA repair deficiency; tumor molecular profiling; immune microenvironment; cardio-oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent years, new insights, novel developments, novel discoveries, and future challenges have radically changed the field of gynecologic oncology.
According to tumor origin, gynecologic malignancies are mainly classified into ovarian cancer (epithelial, germ cell tumor, sexual-stromal tumor, and others), endometrial cancer, cervical cancer, and vulvar cancer, which are recognized as global health threats for women. Over recent decades, multimodal strategies consisting of surgery, radiation, and chemotherapy have been the main choices for the treatment of patients with gynecologic malignancies.
This research topic aims at providing updates on newly identified molecular targets and developed therapeutic strategies for gynecological cancers. It also aims to facilitate the discussion of recent advances in the screening, diagnosis, therapies, and prognosis of gynecological cancers. We welcome article submissions that provide novel information in the fields encompassing, but not limited to, the identification of cancer signaling pathways, potential therapeutic target discoveries, and the development of new targeted drugs and therapeutic strategies for gynecological cancers. These will help to highlight current knowledge in this research area as well as of trends in the targeted therapy of gynecological cancers.
Subtopics of interests include, but are not limited to, the following:
- Identifications of novel biomarkers for diagnosis, therapies, or prognosis for different types of gynecological cancers.
- Combinational therapeutic strategies (chemotherapy, immunotherapy, targeted agents, and radiotherapy) for gynecological cancers.
- Treatment resistance strategies and mechanisms of gynecological cancers and corresponding potential therapies.
- Novel drugs for gynecological cancers.
Dr. Alberto Farolfi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted therapy
- precision medicine
- gynecological cancers
- ovarian cancer
- endometrial cancer
- cervical cancer
